When do you start losing weight on Wegovy — and what to expect each month

The myth that Wegovy works quickly, and why the first few weeks can mislead you

A lot of people starting Wegovy expect to see the scales move dramatically in week one or two. Some do lose a little, largely water weight and reduced bloating as food intake falls and gastric emptying slows. But the honest picture is that 0.25 mg, the dose you start on, is a tolerability dose. Its job is to get your body used to semaglutide without overwhelming you with nausea. The weight-loss effect at that level is minimal by design.

This catches people off guard. They've read about 15% average losses and expect those losses to start arriving immediately. They don't. The trajectory on Wegovy is a slow build, not a fast drop. Understanding that early on saves a lot of unnecessary anxiety, and prevents people from abandoning treatment before it has had a chance to work. If you want a closer look at what the first weeks actually feel like, the page on when weight loss starts on Wegovy goes into the early phase in more detail.

The other thing worth knowing: some people experience noticeable nausea in the first few weeks, which can itself reduce how much they eat. Any weight loss driven by nausea alone tends not to last once the body adjusts. Sustainable loss comes later, from the genuine appetite-regulating effect of semaglutide at therapeutic doses.

Months two to six: where most of the loss happens

As the dose steps up (from 0.25 mg to 0.5 mg, then 1.0 mg, 1.7 mg, and eventually the 2.4 mg maintenance dose) the effect on appetite and satiety becomes progressively stronger. Most people report that hunger genuinely quietens somewhere between the 1.0 mg and 1.7 mg stages. Portions that once felt normal start feeling like too much. That internal signal, when it properly arrives, is when meaningful weight loss tends to accelerate.

In clinical trial data, the steepest part of the weight-loss curve falls in roughly this window. By the 16-week mark, average losses in the STEP 1 trial were already substantial, even though the full 15% average wasn't reached until week 68. The practical takeaway: if you're at month two and feel like nothing is happening, check your trend rather than any single weigh-in. Weighing yourself on the same day each week, at the same time of day, gives a cleaner picture than daily readings, which can swing with hydration and meal timing. That one-minute habit (same day, same time, write it down) is far more useful than daily monitoring for spotting a genuine trend.

For a more detailed look at when the largest drops tend to occur, the page on when you lose the most weight on Wegovy covers that phase specifically.

What can slow (or speed up) your timeline

The 15% average in the STEP 1 trial is exactly that: an average. Some participants lost considerably more; others less. Several factors influence where on that spectrum you land.

Dose adherence matters a great deal. Skipping injections or staying at a lower dose longer than clinically recommended both blunt the effect. Equally, lifestyle factors that run alongside treatment (protein intake, regular movement, sleep quality) are not just background noise. The NHS semaglutide guidance is clear that Wegovy is licensed for use alongside a reduced-calorie diet and increased physical activity, not as a standalone intervention. Practical guidance on getting those elements right is on the page about how to lose weight on Wegovy.

Your starting BMI also plays a role. People with higher starting weights tend to see larger absolute losses even if the percentage is similar. Metabolic conditions (insulin resistance, hypothyroidism) can slow the response. And there's a genuine biological variation between individuals in how strongly they respond to GLP-1 receptor agonists. None of this means treatment isn't working; it means the timeline is personal. A prescriber can help interpret whether your rate of loss falls within a normal range for you, or whether something needs adjusting. Understanding more about who loses weight on semaglutide and to what degree can help set realistic expectations before you start.

One note on cost: the length of treatment affects the overall spend. If you're thinking about the financial picture alongside the clinical one, our Wegovy pricing page explains how private treatment is costed and what's included in a transparent service.

After six months: what happens to the rate of loss

Weight loss on Wegovy does not continue at the same rate indefinitely. Most people reach a new equilibrium (sometimes called a plateau) somewhere between months six and twelve at their maintenance dose. This is normal physiology, not a sign that the medicine has stopped working. The body adapts its energy expenditure as weight falls, which means the same dose eventually produces smaller additional losses. This is why long-term follow-up in clinical trials and ongoing prescriber review both matter.

The NICE recommendation for semaglutide (TA875) includes a review at six months on the maintenance dose: if weight loss hasn't reached at least 5%, continuing is reconsidered. That threshold exists because the evidence for benefit below it is weak. Private prescribers apply a similar clinical lens. The semaglutide overview covers the licensed context and what the guidance says about duration of use. For anyone wondering whether the newer higher dose of 7.2 mg changes this picture (early data suggest it narrows the gap with tirzepatide at 15 mg) that detail sits within the broader Wegovy treatment guide. The direction of travel on dose optimisation is still evolving, and your prescriber is best placed to discuss what's appropriate for you.